$KACLF
Kairous Acquisition Corp. Ltd

2024 Q3 Form 10-Q Financial Statement

#000149315224046374 Filed on November 18, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $230.8K
YoY Change -35.44%
Operating Profit -$230.8K
YoY Change -35.44%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $213.9K
YoY Change -28.63%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$16.89K
YoY Change -70.78%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.100K
YoY Change
Cash & Equivalents $6.103K
Short-Term Investments
Other Short-Term Assets $38.43K
YoY Change -3.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $44.53K
YoY Change -1.19%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $16.52M
YoY Change -29.6%
Other Assets
YoY Change
Total Long-Term Assets $16.52M
YoY Change -29.61%
TOTAL ASSETS
Total Short-Term Assets $44.53K
Total Long-Term Assets $16.52M
Total Assets $16.56M
YoY Change -29.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $416.3K
YoY Change 66.52%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $3.145M
YoY Change 76.68%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.561M
YoY Change 75.08%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $2.730M
YoY Change 0.0%
Total Long-Term Liabilities $2.730M
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.561M
Total Long-Term Liabilities $2.730M
Total Liabilities $6.291M
YoY Change 32.06%
SHAREHOLDERS EQUITY
Retained Earnings -$6.247M
YoY Change 32.37%
Common Stock $235.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.247M
YoY Change
Total Liabilities & Shareholders Equity $16.56M
YoY Change -29.55%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$16.89K
YoY Change -70.78%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$88.35K
YoY Change -55.42%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$150.0K
YoY Change -58.33%
Cash From Investing Activities -$150.0K
YoY Change -58.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $243.5K
YoY Change -53.36%
NET CHANGE
Cash From Operating Activities -$88.35K
Cash From Investing Activities -$150.0K
Cash From Financing Activities $243.5K
Net Change In Cash $5.118K
YoY Change -114.13%
FREE CASH FLOW
Cash From Operating Activities -$88.35K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001865468
CY2024Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
15000 usd
CY2023Q3 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
15000 usd
CY2024Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q3 dei Entity File Number
EntityFileNumber
001-41155
CY2024Q3 dei Entity Registrant Name
EntityRegistrantName
Kairous Acquisition Corp. Limited
CY2024Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2024Q3 dei City Area Code
CityAreaCode
+662
CY2024Q3 KACL Temporary Equity Remeasurement Adjustment Of Carrying Value To Redemption Amount
TemporaryEquityRemeasurementAdjustmentOfCarryingValueToRedemptionAmount
363883 usd
CY2024Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2024Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
usd
CY2024Q3 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
usd
CY2023Q3 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
usd
CY2024Q3 KACL Management Fees Expense
ManagementFeesExpense
usd
CY2023Q3 us-gaap Management Fee Expense
ManagementFeeExpense
usd
CY2024Q3 dei Document Type
DocumentType
10-Q
CY2024Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
Level 39 Marina Bay Financial Centre Tower 2
CY2024Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
10 Marina Boulevard
CY2024Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
City Singapore
CY2024Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
018983
CY2024Q3 dei Entity Address Country
EntityAddressCountry
SG
CY2024Q3 dei Local Phone Number
LocalPhoneNumber
255-6851340
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q3 dei Entity Shell Company
EntityShellCompany
true
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3683906 shares
CY2024Q3 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6103 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
985 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
38426 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
72202 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
44529 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
73187 usd
CY2024Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
16515991 usd
CY2024Q2 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
16152108 usd
CY2024Q3 us-gaap Assets
Assets
16560520 usd
CY2024Q2 us-gaap Assets
Assets
16225295 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
416300 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
307654 usd
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
1940000 usd
CY2024Q2 us-gaap Loans Payable Current
LoansPayableCurrent
1790000 usd
CY2024Q3 KACL Working Capital Loans Sponsor
WorkingCapitalLoansSponsor
1204840 usd
CY2024Q2 KACL Working Capital Loans Sponsor
WorkingCapitalLoansSponsor
1111370 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3561140 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3209024 usd
CY2024Q3 KACL Deferred Underwriting Commission Non Current
DeferredUnderwritingCommissionNonCurrent
2730000 usd
CY2024Q2 KACL Deferred Underwriting Commission Non Current
DeferredUnderwritingCommissionNonCurrent
2730000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
6291140 usd
CY2024Q2 us-gaap Liabilities
Liabilities
5939024 usd
CY2024Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1337763 shares
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1337763 shares
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16515991 usd
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16152108 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2346143 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2346143 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2346143 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2346143 shares
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1337763 shares
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1337763 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
235 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
235 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6246846 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5866072 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-6246611 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-5865837 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16560520 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16225295 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
215774 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
342484 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
230774 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
357484 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-230774 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-357484 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
1 usd
CY2024Q3 us-gaap Investment Income Net
InvestmentIncomeNet
213883 usd
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
299668 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
213883 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
299669 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16891 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-57815 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4001469 usd
CY2023Q3 KACL Temporary Equity Remeasurement To Redemption Value Adjustment
TemporaryEquityRemeasurementToRedemptionValueAdjustment
-659668 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-57815 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-4718952 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-5865837 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-5865837 usd
CY2024Q3 KACL Temporary Equity Remeasurement To Redemption Value Adjustment
TemporaryEquityRemeasurementToRedemptionValueAdjustment
-363883 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16891 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-6246611 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-6246611 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16891 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-57815 usd
CY2024Q3 us-gaap Investment Income Net
InvestmentIncomeNet
213883 usd
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
299668 usd
CY2024Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33776 usd
CY2023Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-30897 usd
CY2024Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
108646 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
128377 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-88352 usd
CY2024Q3 KACL Threshold Percentage Of Public Shares Subject To Redemption Without Companys Prior Written Consent
ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent
0.15 pure
CY2024Q3 KACL Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1 pure
CY2024Q3 KACL Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1 pure
CY2024Q3 KACL Maximum Net Interest To Pay Dissolution Expenses
MaximumNetInterestToPayDissolutionExpenses
50000 usd
CY2023Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
50000 usd
CY2024Q3 KACL Working Capital Deficit
WorkingCapitalDeficit
3516611 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6103 usd
CY2024Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_847_eus-gaap--UseOfEstimates_zq67nSFJKwG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zDbUNLTPM6B2">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
985 usd
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16515991 usd
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16152108 usd
CY2024Q3 KACL Offering Costs Associated With Initial Public Offering
OfferingCostsAssociatedWithInitialPublicOffering
<p id="xdx_842_ecustom--OfferingCostsAssociatedWithInitialPublicOffering_zLypZTL4ehI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zC1Ibf7o3h88">Offering Costs associated with the Initial Public Offering</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the requirements of the Financial Accounting Standards Board (“FASB”) ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A, <i>“Expenses of Offering.”</i> Offering costs of $<span id="xdx_901_eus-gaap--OperatingCostsAndExpenses_c20240701__20240930_zJIJ0nUEhEuc" title="Operating costs and expenses">894,582</span> consisted principally of costs incurred in connection with preparation for the Initial Public Offering. These offering costs, together with the underwriter fees of $<span id="xdx_90A_eus-gaap--PaymentsForUnderwritingExpense_c20240701__20240930_zxUODklD6Nv3" title="Underwriter fees">4,289,900</span> (or $<span id="xdx_909_eus-gaap--PaymentsForUnderwritingExpense_c20240701__20240930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRJYzdHA8lEh" title="Payment for underwriting expense">1,559,900</span> paid in cash upon the closing of the Initial Public Offering and a deferred fee of $<span id="xdx_901_eus-gaap--OtherUnderwritingExpense_c20240701__20240930__us-gaap--SubsidiarySaleOfStockAxis__custom--DeferredUnderwritingCommissionsMember_zIYQEKICBeo" title="Deferred underwriter fees">2,730,000</span>), were charged to stockholders’ equity upon completion of the Initial Public Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
894582 usd
CY2024Q3 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
4289900 usd
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1337763 shares
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1337763 shares
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16515991 usd
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16152108 usd
CY2023Q2 KACL Temporary Equity Gross Proceeds
TemporaryEquityGrossProceeds
78000000 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-198209 usd
CY2024Q3 KACL Cash Deposited Into Trust Account
CashDepositedIntoTrustAccount
150000 usd
CY2023Q3 KACL Cash Deposited Into Trust Account
CashDepositedIntoTrustAccount
360000 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-150000 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-360000 usd
CY2024Q3 us-gaap Proceeds From Issuance Of Unsecured Debt
ProceedsFromIssuanceOfUnsecuredDebt
150000 usd
CY2023Q3 us-gaap Proceeds From Issuance Of Unsecured Debt
ProceedsFromIssuanceOfUnsecuredDebt
360000 usd
CY2024Q3 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
93470 usd
CY2023Q3 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
162000 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
243470 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
522000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5118 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36209 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
985 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39359 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6103 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3150 usd
CY2024Q3 KACL Current Period Remeasurement Adjustment Of Ordinary Shares To Redemption Value
CurrentPeriodRemeasurementAdjustmentOfOrdinarySharesToRedemptionValue
363883 usd
CY2023Q3 KACL Current Period Remeasurement Adjustment Of Ordinary Shares To Redemption Value
CurrentPeriodRemeasurementAdjustmentOfOrdinarySharesToRedemptionValue
659668 usd
CY2021Q4 us-gaap Noninterest Expense Offering Cost
NoninterestExpenseOfferingCost
4843252 usd
CY2021Q4 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
1559900 usd
CY2021Q4 us-gaap Other Underwriting Expense
OtherUnderwritingExpense
2730000 usd
CY2021Q4 KACL Other Offering Costs
OtherOfferingCosts
553352 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
2730000 usd
CY2024Q3 KACL Condition For Future Business Combination Use Of Proceeds Percentage
ConditionForFutureBusinessCombinationUseOfProceedsPercentage
0.80 pure
CY2024Q3 KACL Condition For Future Business Combination Threshold Percentage Ownership
ConditionForFutureBusinessCombinationThresholdPercentageOwnership
0.50 pure
CY2024Q3 KACL Threshold Percentage Of Public Shares Subject To Redemption Without Companys Prior Written Consent
ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent
0.15 pure
CY2024Q3 KACL Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1 pure
CY2024Q3 KACL Redemption Period Upon Closure
RedemptionPeriodUponClosure
P12M
CY2024Q3 KACL Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1 pure
CY2024Q3 KACL Maximum Net Interest To Pay Dissolution Expenses
MaximumNetInterestToPayDissolutionExpenses
50000 usd
CY2023Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
50000 usd
CY2024Q3 KACL Working Capital Deficit
WorkingCapitalDeficit
3516611 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6103 usd
CY2024Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_847_eus-gaap--UseOfEstimates_zq67nSFJKwG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zDbUNLTPM6B2">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6103 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
985 usd
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16515991 usd
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16152108 usd
CY2024Q3 KACL Offering Costs Associated With Initial Public Offering
OfferingCostsAssociatedWithInitialPublicOffering
<p id="xdx_842_ecustom--OfferingCostsAssociatedWithInitialPublicOffering_zLypZTL4ehI4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zC1Ibf7o3h88">Offering Costs associated with the Initial Public Offering</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the requirements of the Financial Accounting Standards Board (“FASB”) ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A, <i>“Expenses of Offering.”</i> Offering costs of $<span id="xdx_901_eus-gaap--OperatingCostsAndExpenses_c20240701__20240930_zJIJ0nUEhEuc" title="Operating costs and expenses">894,582</span> consisted principally of costs incurred in connection with preparation for the Initial Public Offering. These offering costs, together with the underwriter fees of $<span id="xdx_90A_eus-gaap--PaymentsForUnderwritingExpense_c20240701__20240930_zxUODklD6Nv3" title="Underwriter fees">4,289,900</span> (or $<span id="xdx_909_eus-gaap--PaymentsForUnderwritingExpense_c20240701__20240930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRJYzdHA8lEh" title="Payment for underwriting expense">1,559,900</span> paid in cash upon the closing of the Initial Public Offering and a deferred fee of $<span id="xdx_901_eus-gaap--OtherUnderwritingExpense_c20240701__20240930__us-gaap--SubsidiarySaleOfStockAxis__custom--DeferredUnderwritingCommissionsMember_zIYQEKICBeo" title="Deferred underwriter fees">2,730,000</span>), were charged to stockholders’ equity upon completion of the Initial Public Offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
894582 usd
CY2024Q3 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
4289900 usd
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1337763 shares
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1337763 shares
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16515991 usd
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16152108 usd
CY2023Q2 KACL Temporary Equity Gross Proceeds
TemporaryEquityGrossProceeds
78000000 usd
CY2023Q2 KACL Transaction Costs Allocated To Ordinary Shares
TransactionCostsAllocatedToOrdinaryShares
-4599397 usd
CY2023Q2 KACL Proceeds Allocated To Public Warrants
ProceedsAllocatedToPublicWarrants
-8275800 usd
CY2023 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
5710184 shares
CY2023 KACL Temporary Equity Gross Proceeds Net
TemporaryEquityGrossProceedsNet
58312401 usd
CY2023Q2 KACL Temporary Equity Remeasurement Adjustment Of Carrying Value To Redemption Amount
TemporaryEquityRemeasurementAdjustmentOfCarryingValueToRedemptionAmount
15989837 usd
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
22802239 usd
CY2024 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
752053 shares
CY2024 KACL Temporary Equity Gross Proceeds Net
TemporaryEquityGrossProceedsNet
8621702 usd
CY2024Q2 KACL Temporary Equity Remeasurement Adjustment Of Carrying Value To Redemption Amount
TemporaryEquityRemeasurementAdjustmentOfCarryingValueToRedemptionAmount
1971571 usd
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16152108 usd
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16515991 usd
CY2024Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zSAcbKlNQdyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zAuRLHsIpc5h">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20240930_zcPtsaUpK603" title="Cah FDIC insured amount">250,000</span>. The Company has not experienced losses on this account. The Company has not experienced any losses on the Trust Account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q2 KACL Transaction Costs Allocated To Ordinary Shares
TransactionCostsAllocatedToOrdinaryShares
-4599397 usd
CY2023Q2 KACL Proceeds Allocated To Public Warrants
ProceedsAllocatedToPublicWarrants
-8275800 usd
CY2023 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
5710184 shares
CY2023 KACL Temporary Equity Gross Proceeds Net
TemporaryEquityGrossProceedsNet
58312401 usd
CY2023Q2 KACL Temporary Equity Remeasurement Adjustment Of Carrying Value To Redemption Amount
TemporaryEquityRemeasurementAdjustmentOfCarryingValueToRedemptionAmount
15989837 usd
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
22802239 usd
CY2024 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
752053 shares
CY2024 KACL Temporary Equity Gross Proceeds Net
TemporaryEquityGrossProceedsNet
8621702 usd
CY2024Q2 KACL Temporary Equity Remeasurement Adjustment Of Carrying Value To Redemption Amount
TemporaryEquityRemeasurementAdjustmentOfCarryingValueToRedemptionAmount
1971571 usd
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16152108 usd
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
16515991 usd
CY2024Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zSAcbKlNQdyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zAuRLHsIpc5h">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20240930_zcPtsaUpK603" title="Cah FDIC insured amount">250,000</span>. The Company has not experienced losses on this account. The Company has not experienced any losses on the Trust Account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q3 KACL Management Fees Expense
ManagementFeesExpense
15000 usd
CY2024Q3 us-gaap Management Fee Expense
ManagementFeeExpense
30000 usd
CY2024Q3 us-gaap Management Fee Payable
ManagementFeePayable
45000 usd
CY2024Q2 us-gaap Management Fee Payable
ManagementFeePayable
30000 usd
CY2024Q3 KACL Working Capital Loans Sponsor
WorkingCapitalLoansSponsor
1204840 usd
CY2024Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
10.10
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1125000 shares
CY2024Q3 KACL Deferred Purchase Fee
DeferredPurchaseFee
100 usd
CY2024Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
39000 shares
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
341230 usd
CY2022Q4 us-gaap Share Price
SharePrice
10.00
CY2023Q2 KACL Advisory Agreement Description
AdvisoryAgreementDescription
The advisory fee is the greater of (a) $2,000,000 and (b) the total of 3% of the first $100 million of merger consideration, 2% of the merger consideration between $100 million and $200 million, and 1% of the merger consideration exceeding $200 million.
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2346143 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2346143 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2346143 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2346143 shares
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1337763 shares
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1337763 shares
CY2024Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Description
SharesSubjectToMandatoryRedemptionSettlementTermsDescription
if, and only if, the reported last sale price of the ordinary shares equals or exceeds $16.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30-trading day period commencing at any time after the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders
CY2023Q3 KACL Management Fees Expense
ManagementFeesExpense
15000 usd
CY2024Q3 us-gaap Management Fee Expense
ManagementFeeExpense
30000 usd
CY2024Q3 us-gaap Management Fee Payable
ManagementFeePayable
45000 usd
CY2024Q2 us-gaap Management Fee Payable
ManagementFeePayable
30000 usd
CY2024Q3 KACL Working Capital Loans Sponsor
WorkingCapitalLoansSponsor
1204840 usd
CY2024Q2 KACL Working Capital Loans Sponsor
WorkingCapitalLoansSponsor
1111370 usd
CY2024Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
10.10
CY2024Q3 KACL Extension Loans
ExtensionLoans
1940000 usd
CY2024Q2 KACL Extension Loans
ExtensionLoans
1790000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1125000 shares
CY2024Q3 KACL Deferred Purchase Fee
DeferredPurchaseFee
100 usd
CY2024Q3 KACL Deferred Underwriting Fee
DeferredUnderwritingFee
105000 usd
CY2024Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
39000 shares
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
341230 usd
CY2022Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
2000000 usd
CY2022Q4 us-gaap Other Underwriting Expense
OtherUnderwritingExpense
2730000 usd
CY2022Q4 us-gaap Share Price
SharePrice
10.00
CY2023Q2 KACL Advisory Agreement Description
AdvisoryAgreementDescription
The advisory fee is the greater of (a) $2,000,000 and (b) the total of 3% of the first $100 million of merger consideration, 2% of the merger consideration between $100 million and $200 million, and 1% of the merger consideration exceeding $200 million.
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2346143 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2346143 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2346143 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2346143 shares
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1337763 shares
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
1337763 shares
CY2024Q3 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Description
SharesSubjectToMandatoryRedemptionSettlementTermsDescription
if, and only if, the reported last sale price of the ordinary shares equals or exceeds $16.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30-trading day period commencing at any time after the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders

Files In Submission

Name View Source Status
0001493152-24-046374-index-headers.html Edgar Link pending
0001493152-24-046374-index.html Edgar Link pending
0001493152-24-046374.txt Edgar Link pending
0001493152-24-046374-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
kacl-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kacl-20240930_cal.xml Edgar Link unprocessable
kacl-20240930_def.xml Edgar Link unprocessable
kacl-20240930_pre.xml Edgar Link unprocessable
kacl-20240930_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending